Dynamics of osteopontin in serum and urine in the early postoperative period after percutaneous nephrolithotomy


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Aim. To evaluate the dynamics of plasma and urine level of osteopontin in the early postoperative period after percutaneous nephrolithotomy (PCNL) in patients with pelvic stones.

Materials and methods. A total of 110 patients with pelvic stones up to 20 mm in size without urinary tract obstruction were included in the study. The patients were divided into two groups based on the results of intraoperative monitoring of intrarenal pressure. In each of the groups, PCNL or mini-PCNL were performed in same proportions. Intraoperative monitoring of intrarenal pressure was done in all cases according to the authors’ method. Sampling of plasma and urine for enzyme immunoassay was performed on the 0, 7 and 30 days after the procedure. Plasma and urine osteopontin level was measured using a commercial Human Osteopontin ELISA Kit for enzyme immunoassay.

Results. In patients with increased intraoperative intrarenal pressure pyelonephritis developed, accompanied by hyperthermia from 3 to 7 days in 70% of cases, and leukocytosis and leukocyturia in 100% of cases. The number of hemorrhagic complications did not differ in both groups. An increase in serum osteopontin level was seen, which was significantly more pronounced in the group with increased intraoperative intrarenal pressure. Urinary osteopontin level, on the contrary, tends to decrease, more pronouncedly in patients with normal intraoperative intrarenal pressure.

Conclusion. The rate of decrease in urinary osteopontin level indicates the stabilization of injury and the restoration of renal function after PCNL. An increase in serum osteopontin level is associated with the development of postoperative inflammatory complications, which demonstrates the immune functions of serum osteopontin.

Texto integral

Acesso é fechado

Sobre autores

D. Khotko

Saratov State Medical University named after V.I. Razumovsky of the Ministry of Health of Russia

Autor responsável pela correspondência
Email: dnksar@list.ru
ORCID ID: 0000-0002-7966-5181

Ph.D., Head of the Department of Urology

Rússia, Saratov

A. Khotko

Saratov State Medical University named after V.I. Razumovsky of the Ministry of Health of Russia

Email: dnksar@list.ru
ORCID ID: 0000-0002-4569-9906

Ph.D., Assistant of the Department of Urology

Rússia, Saratov

V. Popkov

Saratov State Medical University named after V.I. Razumovsky of the Ministry of Health of Russia

Email: dnksar@list.ru
ORCID ID: 0000-0003-2876-9607

Ph.D., MD, Head of the Department of Urology

Rússia, Saratov

A. Tarasenko

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)

Email: dnksar@list.ru
ORCID ID: 0000-0002-3258-8174

Ph.D., Deputy Director on Innovative Development of the Institute of Urology and Reproductive Health

Rússia, Moscow

Bibliografia

  1. Kaprin A.D., Apolikhin O.I., Sivkov A.V., Anokhin N.V., Gadzhiev N.K., Malkhasyan V.A., Akopyan G.N., Prosyannikov M.Yu. The incidence of urolithiasis in the Russian Federation from 2005 to 2020. Experimental and Clinical Urology. 2022;15(2):10–17; https://doi.org/10.29188/2222-8543-2022-15-2-10-17.
  2. Martov A.G., Dutov S.V., Popov S.V. et al. Mini-percutaneous laser nephro- lithotripsy. Urologiia. 2019;3:72–79.
  3. Cicek M.C., Asi T., Gunseren K.O., Kilicarslan H. Comparison of laparoscopic pyelolithotomy and retrograde intrarenal surgery in the management of large renal pelvic stones. Int. J. Clin. Pract. 2021;75(6):14093.
  4. Perepanova T.S., Merinov D.S., Kazachenko A.V., Tolordava E.L., Malova Yu.A. Prevention of infectious and inflammatory complications after percutaneous nephrolithotripsy using the drug pyobacteriophage. Experimental and Clinical Urology. 2019;(1)132–138. doi: 10.29188/2222-8543-2019-11-1-132-138.
  5. Khotko D.N., Khotko A.I., Popkov V.M., Tarasenko A.I., Efimova A.O. The role of intraoperative intrarenal pressure in the postoperative period of percutaneous nephrolithotripsy in patients with urolithiasis. Experimental and Clinical Urology. 2022;15(3)82–87 https://doi.org/10.29188/2222-8543-2022-15-3-82-87.
  6. Khotko A.I., Khotko D.N., Zakharova N. B., Tarasenko A.I., Popkov V.M., Alekseev A.V. Effectiveness of the calcium channel blocker lercanidipine as a nephroprotector in the treatment of patients with urolithiasis with obstructive syndrome and monitoring of the cytokine profile of blood. Urologiia. 2019;5:48–52.
  7. Franzén A., Heinegård D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. 1985;232:715–724.
  8. Kosmopoulos M., Paschou S.A., Grapsa J., Anagnostis P., Vryonidou A., Goulis D.G., Siasos G. The Emerging Role of Bone Markers in Diagnosis and Risk Stratification of Patients With Coronary Artery Disease. Angiology. 2019;70:690–700.
  9. Iida T., Wagatsuma K., Hirayama D., Nakase H. Is Osteopontin a Friend or Foe of Cell Apoptosis in Inflammatory Gastrointestinal and Liver Diseases? Int. J. Mol. Sci. 2017;19:7.
  10. Rittling S.R., Singh R. Osteopontin in Immune-mediated Diseases. J. Dent. Res. 2015;94:1638–1645.
  11. Castello L.M., Raineri D., Salmi L. et al. Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediat. Inflamm. 2017;2017:4049098.
  12. Zhu Q., Luo X., Zhang J., Liu Y., Luo H., Huang Q., Cheng Y., Xie Z. Osteopontin as a Potential Therapeutic Target for Ischemic Stroke. Curr. Drug Deliv. 2017;14:766–772.
  13. Bevan L., Lim Z.W., Venkatesh B., Riley P.R., Martin P., Richardson R.J. Specific macrophage populations promote both cardiac scar deposition and subsequent resolution in adult zebrafish. Cardiovasc. Res. 2020;116:1357–1371.
  14. Zhao H., Chen Q., Alam A., Cui J., Suen K.C., Soo A.P., Eguchi S., Gu J., Ma D. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018;9:356.
  15. Chimento S., Billero V., Cavallin L., Romanelli M., Nadji M., Romanelli P. Evaluation of osteopontin expression in chronic wounds: A potential prognostic and therapeutic biomarker. J. Wound Care. 2017;26:S4–S8.
  16. Bruemmer D., Collins A.R., Noh G. et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J. Clin. Investig. 2003;112:1318–1331.
  17. Zhang Z.X., Shek K., Wang S., Huang X., Lau A., Yin Z. Osteopontin expressed in tubular epithelial cells regulates NK cell-mediated kidney ischemia reperfusion injury. Journal of Immunology. 2010;185:967–973.
  18. Inoue M., Shinohara M.L. Intracellular osteopontin (iOPN) and immunity. Immunologic Research. 2011;49:160–172.
  19. Chen Q., Shou P., Zhang L., Xu C., Zheng C., Han Y. An osteopontin-integrin interaction plays a critical role in directing adipogenesis and osteogenesis by mesenchymal stem cells. Stem Cells. 2014;32(2):327–337.
  20. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:2302–2309.
  21. Collins A.R., Schnee J., Wang W., Kim S., Fishbein M.C., Bruemmer D. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. Journal of the American College of Cardiology. 2004;43:1698–1705.
  22. Nomiyama T., Perez-Tilve D., Ogawa D., Gizard F., Zhao Y., Heywood E.B. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. Journal of Clinical Investigation. 2007;117:2877–2888.
  23. Wanigasuriya L.K., Jayawardene I., Amaraslrlwardanav C., Wickremasinghe R. Novel urinary biomarkers and their association with urinary heavy metals in chronic kidney disease of unknown aetiology in Sri Lank: a pilot study. Ceylon Med. J. 2017;62:210–217. Doi: http://doLorgllO.4038/cmj.v62i4.8568.
  24. Sekiguchi K., Matsuda A., Yamada M. et al. The utility of serum osteopontin levels for predicting postoperative complications after colorectal cancer surgery. Int J Clin Oncol. 2022;27(11):1706–1716. doi: 10.1007/s10147-022-02225-6. Epub 2022 Aug 11.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2. Fig.1. Intrapelvic pressure sensor. A - way to install the pressure sensor; B - diagram of the structure of the sensor

Baixar (251KB)
Metadados
3. Fig.2. Dynamics of the level of serum OPN (pg / ml) in the 1st (A) and 2nd (B) groups

Baixar (204KB)
Metadados
4. Fig.3. Dynamics of the level of urinary OPN (in pg/ml) in the 1st (A) and 2nd (B) groups

Baixar (209KB)
Metadados

Declaração de direitos autorais © Bionika Media, 2023

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies